ContraFect Corporation (Nasdaq:CFRX), a
clinical-stage biotechnology company focused on the discovery and
development of protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, today
announced the presentation of new data on its lead drug candidate,
CF-301 (exebacase), and its Gram-negative lysin discovery program
at American Society for Microbiology (ASM) Microbe 2018, to be held
from June 7-11, 2018, in Atlanta.
The presentations include results from new in
vivo, in vitro, and surveillance studies of ContraFect’s lead
lysin CF-301 (exebacase), which is currently being studied in a
Phase 2 clinical trial for the treatment of Staphylococcus aureus
(Staph aureus) bacteremia, including endocarditis. Data will be
presented which demonstrates CF-301’s activity against a broad
range of Staphylococcus and Streptococcus bacteria known to cause
bacteremia and endocarditis, activity against contemporary clinical
isolates of Staph aureus from U.S. hospitals, and ability to
suppress emergence of vancomycin resistance. For the first time,
data on CF-301’s novel ability to synergize with and activate host
factors in human serum will be presented. ContraFect will also
present initial in vitro proof of principle data from the
Gram-negative lysin discovery program demonstrating the
bactericidal effect of its newly discovered lysins against
multi-drug resistant (MDR) Pseudomonas aeruginosa.
“We are pleased to return to ASM this year and
present important new data which expands our understanding of
CF-301’s spectrum of action of against a broad range of Staph and
Strep species and provides new insight into the compound’s novel
ability to activate latent host factors in human blood which
enhance bactericidal activity,” said Cara Cassino, M.D., Chief
Medical Officer and Executive Vice President of Research and
Development at ContraFect. “We are also excited to unveil the first
data on the bactericidal and anti-biofilm activity of Gram-negative
lysins discovered in our laboratory against MDR Pseudomonas
aeruginosa. We look forward to continuing to present new data from
our active lysin research programs as we await top-line results
from the ongoing Phase 2 trial of CF-301 later this year,”
continued Dr. Cassino.
Presentation Details:
Presentation
Title: Bacteriophage Lysins Can Be
Engineered to Exert a Rapid and Potent Bactericidal Effect against
Pseudomonas aeruginosa in Serum Session Day &
Time: Sunday, June 10, 2018, 12:45 p.m. – 2:45 p.m.
ET Poster Board Number: SUNDAY - HMB LB14
Session Title: Session 384 - SUNDAY - HMB
Late-breakers
Presentation Title: Lysin
CF-301 Demonstrates Potent in Vitro Activity against a Range of
Staphylococcus and Streptococcus Species Associated with
Complicated Bacteremia and Infective Endocarditis in Humans
Session Day & Time: Sunday, June 10,
2018, 12:45 p.m. – 2:45 p.m. ET Poster Board
Number: SUNDAY - AAR LB5 Session
Title: Session 403 - SUNDAY - AAR Late-breakers
Presentation
Title: CF-301 Activity versus
Contemporary Staphylococcus aureus Clinical Isolates from US
Hospitals Session Day & Time: Sunday,
June 10, 2018, 12:45 p.m. – 2:45 p.m. ET Poster Board
Number: SUNDAY - 530 Session
Title: Session 410 - AAR08 - New Antimicrobial Agents
and New Research Technologies: Bacteriophage-Related Tools and
Therapy
Presentation Title: Lysin
CF-301 Administered in Addition to Vancomycin (VAN) Suppresses the
Emergence of Reduced Susceptibilities to VAN Within Cardiac
Vegetations in A Rabbit Model of MRSA Infective Endocarditis (IE)
Session Day & Time: Sunday, June 10,
2018, 12:45 p.m. – 2:45 p.m. ET Poster Board
Number: SUNDAY - 535 Session
Title: Session 410 - AAR08 - New Antimicrobial Agents
and New Research Technologies: Bacteriophage-Related Tools and
Therapy
Presentation Title: Lysin
CF-301 Activates Latent Host Factors in Human Blood to Potentiate
Bacteriolysis Session Day & Time: Sunday,
June 10, 2018, 12:45 p.m. – 2:45 p.m. ET Poster Board
Number: SUNDAY - 536 Session
Title: Session 410 - AAR08 - New Antimicrobial Agents
and New Research Technologies: Bacteriophage-Related Tools and
Therapy
The abstracts can be accessed through the ASM Microbe
website. Following the meeting, the presentation posters will be
available on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing therapeutic protein and antibody
products for life-threatening, drug-resistant infectious diseases,
particularly those treated in hospital settings. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our lysin and monoclonal antibody platforms to target
conserved regions of either bacteria or viruses (regions that are
not prone to mutation). ContraFect's initial product candidates
include new agents to treat antibiotic-resistant infections such as
MRSA (Methicillin-resistant Staph aureus) and influenza.
ContraFect’s lead product candidate, CF-301, is currently in a
Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis and is the first lysin to enter
clinical studies in the U.S. ContraFect is also conducting
research focused on the discovery of lysins to target Gram-negative
bacteria.
About CF-301 (exebacase):
CF-301 (exebacase) is a recombinant
bacteriophage-derived lysin with potent bactericidal activity
against Staph aureus, a major cause of blood stream infections, or
bacteremia. CF-301 has the potential to be a first-in-class
treatment for Staph aureus bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus
and does not impact the body's natural bacterial flora. By
targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to CF-301.
Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
CF-301 was licensed from The Rockefeller University and is being
developed at ContraFect. It is the first lysin to enter clinical
studies in the U.S.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding new data and
results on CF-301 and ContraFect’s Gram-negative lysin discovery
program, our ability to discover and develop protein and antibody
therapeutics for life-threatening, drug-resistant infectious
diseases, our ability to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses, whether our initial product candidates can treat
antibiotic-resistant infections such as MRSA and influenza, our
ability to discover new lysins targeting Gram-negative bacteria,
the potential for CF-301 to be a treatment for Staph aureus
bacteremia, including endocarditis, our ability to obtain top-line
results from the ongoing Phase 2 trial later this year, in vivo, in
vitro and surveillance studies, data on bactericidal and
anti-biofilm activity of Gram-negative lysins against MDR
Pseudomonas aeruginosa and statements made regarding presentations.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024